Calocurb Limited

Calocurb Limited - Capital Raise

Venture Capital

Register Interest


The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
NZD $5,000,000.00
Share Price
NZD $763.00
Minimum Investment
NZD $15,000.00
Issue Type
Venture Capital
Health Care

Calocurb Ltd ( calocurb.com and calocurb.co.nz) was founded in 2018. Its active ingredient Amarasate™ was developed by NZ’s largest Government owned research institute over 6 years and a $20m grant. 

Calocurb is a unique supplement it is: 

  •  A patented world first ‘Appetite Suppressant’ that utilises the ‘bitter break’ mechanism to suppress hunger 
  • It is clinically proven and published to reduce hunger by up to 80% and calorie intake by 18%
  • It does this by stimulating the natural release of GLP-1 and other appetite suppressing hormones ( CCK , PYY) . Calocurbs closest competitors are Semaglutide injectables such as Wegovy ( Novo Nordisk) which are taking the world by storm (currently sold out worldwide with sales of US $1.6B in 2021)
  • The formulation and delivery mechanism have a patent pending in NZ, Australia, US and Europe
  • It is 100% natural, with only 3 plant based ingredients – no chemicals of fillers i.e. no bloating 
  • No stimulants or caffeine i.e. no jitters or disturbed sleep 
  • No sugar, no calories 
  • Manufactured in the US 


Calocurb has sold over 65,000 units Direct to Consumer in NZ, Australia and the US to date. It also sells wholesale to Chemist Warehouse in New Zealand and began shipping to China in September.

It raised a small amount of capital last year to complete the 3rd human clinical (results currently being published) , secure available raw material/extract and refresh US assets. This larger capital raise is to provide scale and complete a weight loss clinical trial.

To view the one pager click here, to view the full Information Memorandum click here.

To be put in contact with the issuer click Reqister Interest.

No items found.

Calocurb Limited

Join our Business/Issuer newsletter

Our quarterly Issuer newsletter is for businesses and issuers, and contains platform updates and business insights.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.